T. Rowe Price Investment Management, Inc. Blueprint Medicines Corp Transaction History
T. Rowe Price Investment Management, Inc.
- $162 Billion
- Q4 2024
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Blueprint Medicines Corp stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 697,027 shares of BPMC stock, worth $63.2 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
697,027
Previous 748,692
6.9%
Holding current value
$63.2 Million
Previous $69.3 Million
12.22%
% of portfolio
0.04%
Previous 0.04%
Shares
10 transactions
Others Institutions Holding BPMC
# of Institutions
379Shares Held
61.6MCall Options Held
1.6MPut Options Held
1.41M-
Vanguard Group Inc Valley Forge, PA6.77MShares$615 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$603 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.68MShares$515 Million0.06% of portfolio
-
State Street Corp Boston, MA2.5MShares$227 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL1.94MShares$176 Million0.44% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.42B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...